Filter your results
- 4
- 1
- 5
- 5
- 1
- 1
- 1
- 1
- 1
- 4
- 1
- 3
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized LipodystrophyDiabetes, 2022, pp.db211172. ⟨10.2337/db21-1172⟩
Journal articles
inserm-03830442v1
|
||
Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1Annals of Surgery, In press, ⟨10.1097/SLA.0000000000003162⟩
Journal articles
hal-01996226v1
|
|||
Alteration of Natural Killer cell phenotype and function in obese individualsClinical Immunology, 2017, 177, pp.12-17. ⟨10.1016/j.clim.2016.01.007⟩
Journal articles
hal-01796182v1
|
|||
Anti-Programmed Death 1 (PD-1) Antibodies and the Pancreas: A Diabetic Storm Ahead?Diabetes Care, 2018, 41 (3), pp.638-639. ⟨10.2337/dc17-2243⟩
Journal articles
hal-01847397v1
|
|||
|
Hypophysites induites par les immunothérapies anti-néoplasiquesBulletin du Cancer, 2020, 107 (4), pp.490--498. ⟨10.1016/j.bulcan.2020.01.012⟩
Journal articles
hal-02901888v1
|